Phase 4CompletedAge-related condition

China Stroke Primary Prevention Trial (CSPPT)

Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial.

Sponsor
Shenzhen Ausa Pharmed Co.,Ltd (Industry)
Enrollment
20,702 enrolled
Conditions
Primary Hypertension
Interventions
Enalapril/folic acid; Enalapril maleate
Ages
adults, older adults
Registry
NCT00794885

Full record on ClinicalTrials.gov

From the registry

The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.

Primary outcomes

  • First attack of symptomatic stroke ( ischemic or hemorrhagic)

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Registered

  5. Started

Papers citing this trial